Asthma and COPD Devices Market Overview
Global Asthma and COPD Devices Market reached US$ 44.85 billion in 2025 and is expected to reach US$ 68.05 billion by 2033 growing with a CAGR of 5.31 % during the forecast period 2026-2033.
The global asthma and COPD devices market is witnessing steady growth due to the rising burden of chronic respiratory diseases, increasing air pollution, smoking-related lung disorders, and growing awareness regarding early disease diagnosis and long-term management. Asthma and chronic obstructive pulmonary disease (COPD) require continuous monitoring and effective drug delivery, which is driving demand for inhalers, nebulizers, spirometers, peak flow meters, and other respiratory care devices. The market is also benefiting from technological advancements such as smart inhalers, portable nebulizers, and connected monitoring systems that improve treatment adherence and patient outcomes. In addition, the growing geriatric population and increasing prevalence of occupational respiratory conditions are supporting market expansion across both developed and emerging regions. Healthcare providers are increasingly focusing on home-based respiratory care, which is further boosting device adoption. With ongoing innovation, improved accessibility, and rising healthcare expenditure, the asthma and COPD devices market is expected to maintain positive growth over the forecast period.
Asthma and COPD Devices Market Scope
| Metrics | Details |
| CAGR | 5.31 % |
| Size Available for Years | 2024-2033 |
| Forecast Period | 2025-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Product, Distribution channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Others key Insights. |
For more details on this report Request for Sample
Asthma and COPD Devices Market Dynamics
Increasing Product Launches for Asthma and COPD Devices
Inhalers and nebulizers are the two main ways inhaled medicine is used to treat asthma and COPD. The product launches by major companies help to drive market growth and these effective research and developments help in product launches and also finding new treatments and improve care for millions of people with asthma and COPD conditions.
For instance, in August 2023, Viatris and Kindeva Drug Delivery LP launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca’s Symbicort. Breyna is a drug-device combination product that is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). It is indicated for asthma patients of 6 years and above.
Additionally, in May 2022, in line with the theme of World Asthma Day “ Closing Gaps In Asthma Carte”, Alkem Laboratories launched Innohaler, a DPI device to make life easier for Asthma and COPD patients. Hence, due to the above factors, the market is expected to boost over the forecast period.
Rising Awareness for Asthma and COPD is Boosting the Asthma and COPD Devices Market
The global asthma and COPD devices market has witnessed significant growth in recent years due to the rising awareness of asthma and COPD conditions. Awareness conducted by government and private organizations for asthma and COPD helps people understand the risks of smoking and chemical exposure. It also helps people with symptoms to seek treatment earlier and could even improve a person's life expectancy.
For instance, in April 2022, VillageMD and the COPD Foundation declared a partnership to better identify and treat chronic obstructive pulmonary disease (COPD) at Village Medical practices. This partnership aims to raise awareness through education and outreach campaigns to patients help identify those with undiagnosed COPD, and increase access to pulmonary rehabilitation.
Additionally, in May 2020, The Florida Department of Health recognizes May as National Asthma Awareness Month and takes the opportunity to educate Floridians regarding diagnosis and treatment programs committed to improving the lives of those living with asthma. The department is working with national and statewide partners to make life better for Floridians with asthma and their families by promoting the use of a tailored, written asthma action plan (AAP) as part of a comprehensive approach to asthma care.
Side Effects Associated with Nebulizer Will Hamper the Growth of the Market
Side effects of using a nebulizer include allergic reactions such as skin rash, itching, hives, and swelling of the face, lips, tongue, or throat. It can also lead to heart rhythm changes, fast or irregular heartbeat, dizziness, feeling faint or lightheaded, chest pain, and trouble breathing. Using of nebulizer can also increase blood pressure and cause muscle cramps or pain. Thus, the above factors are expected to hamper the market growth.
Asthma and COPD Devices Market Segment Analysis
The global asthma and COPD devices market is segmented based on product, distribution channel, and region.
Inhalers from the Product Segment Accounted for Approximately XX% of the Global Asthma and COPD Devices Market Share
Asthma inhalers are hand-held, portable devices that deliver medication to the lungs. Doctors suggest the use of inhaled corticosteroids (ICS) to prevent asthma symptoms along with a rescue inhaler for quick relief of attacks. Inhalers are expected to hold the largest market share over the period forecast owing to increasing product launches.
For instance, in July 2023, Teva UK launched a new GoResp Digihaler system in the United Kingdom. GoResp Digihaler is the first integrated inhaler device with built-in sensors that detect and record objective data on the patient’s use and ability to use their inhaler including inspiratory flow classification.
Additionally, in July 2023, Hormosan Pharma GmbH, a wholly-owned subsidiary of the Lupin company in Germany, launched Luforbec, a pressurized metered dose inhaler in the European nation. Luforbec is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist is suitable.
Asthma and COPD Devices Marke Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share in 2022
The global asthma and COPD devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the asthma and COPD devices market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence and incidence of asthma conditions, and product approvals in asthma and COPD devices.
For instance, according to the Asthma and Allergy Foundation of America 2023, nearly 26 million people in the U.S. have asthma and this equals about 1 in 13 people. Nearly 21 million U.S. adults ages 18 and older have asthma. Asthma is more common in female adults than in male adults. Around 9.7% of female adults have asthma, compared to 6.2% of male adults.
Additionally, in January 2023, Airsupra (albuterol/budesonide) was approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide.
Competitive Landscape
The major global players in the market include GlaxoSmithKline Plc., Novartis AG, AstraZeneca Plc., Pfizer Inc., Lepu Medical Technology Co. Ltd., Omron Healthcare Co. Ltd., Trudell Medical International, Beurer GmbH, Merck KGaA, PARI GmbH among others.
Key Developments
- In May 2025, AstraZeneca PLC announced that Trixeo Aerosphere became its first inhaled respiratory medicine in the UK to use a next-generation propellant with near-zero global warming potential, supporting both COPD treatment innovation and sustainability goals.
- In November 2025, OMRON Corporation announced that its cumulative global sales of nebulizers surpassed 50 million units, highlighting the increasing adoption of home-based respiratory care devices for the management of asthma and COPD.
Why Purchase the Report?
- To visualize the global asthma and COPD devices market segmentation based on product, distribution channel, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global asthma and COPD devices market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global asthma and COPD devices market report would provide approximately 69 tables, 70 figures, and 195 Pages.
